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Abstract
Introduction We examined the association between
mammographic density and single-nucleotide polymorphisms
(SNPs) in genes encoding CYP1A1, CYP1B1, aromatase, 17β-
HSD, ESR1, and ESR2 in pre- and early perimenopausal white,
African-American, Chinese, and Japanese women.
Methods The Study of Women's Health Across the Nation is a
longitudinal community-based cohort study. We analyzed data
from 451 pre- and early perimenopausal participants of the
ancillary SWAN Mammographic Density study for whom we had
complete information regarding mammographic density,
genotypes, and covariates. With multivariate linear regression,
we examined the relation between percentage mammographic
breast density (outcome) and each SNP (primary predictor),
adjusting for age, race/ethnicity, parity, cigarette smoking, and
body mass index (BMI).
Results After multivariate adjustment, the CYP1B1 rs162555
CC genotype was associated with a 9.4% higher
mammographic density than the TC/TT genotype (P = 0.04).
The CYP19A1 rs936306 TT genotype was associated with
6.2% lower mammographic density than the TC/CC genotype
(P = 0.02). The positive association between CYP1A1
rs2606345 and mammographic density was significantly
stronger among participants with BMI greater than 30 kg/m2
than among those with BMI less than 25 kg/m2 (Pinteraction =
0.05). Among white participants, the ESR1 rs2234693 CC
genotype was associated with a 7.0% higher mammographic
density than the CT/TT genotype (P = 0.01).
Conclusions SNPs in certain genes encoding sex steroid
metabolism enzymes and ESRs were associated with
mammographic density. Because the encoded enzymes and
ESR1 are expressed in breast tissue, these SNPs may influence
breast cancer risk by altering mammographic density.
Introduction
High mammographic breast density, the density of the breast
on mammography, is one of the strongest known risk factors
for breast cancer [1]. High breast density (dense tissue on
50% or more of the breast) could account for up to one third
of breast cancer cases [2]. Factors such as body mass index,
parity, age, smoking, and physical activity jointly account for
only a small proportion of the variability in mammographic den-
sity [3]. In contrast, mammographic density has a strong
genetic component. Twin studies have demonstrated that her-Page 1 of 15
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tors) accounts for 60% of the variance in mammographic
density [4,5].
It is feasible that genetic variation in sex steroids or in estrogen
receptors (ESRs) produced in breast tissue could lead to dif-
fering degrees of proliferation that may be manifest radio-
graphically as interindividual differences in mammographic
density. The presence of sex steroid metabolic enzymes and
ESRs in breast tissue [6-24] suggests that local activation of
estrogen to potentially reactive metabolites within breast tis-
sue may play a role in initiating and promoting carcinogenesis
[18]. Such enzymes include CYP1A1, CYP1B1, and 17β-
hydroxysteroid dehydrogenase (17β-HSD). In addition to
metabolizing environmental carcinogens (for example, polycy-
clic aromatic hydrocarbons), CYP1A1 has high activity with
the 17β-estradiol substrate [25,26]. CYP1A1 forms mainly 2-
hydroxyestrone, and to a lesser degree, some 4-hydrox-
yestrone, from estrone. In contrast, CYP1B1 predominantly
catalyzes formation of potentially carcinogenic catechol estro-
gens, especially 4-hydroxyestrogens [6,26-28]. The implica-
tion of 4-hydroxy catechol estrogens in carcinogenesis
suggests a key role for CYP1B1 in carcinogenesis
[19,27,29,30]. CYP19A1 is the gene encoding the aromatase
enzyme that catalyzes the formation of aromatic C18 estro-
gens from C19 androgens [6,31]. Type I 17β-HSD is the
enzyme responsible for interconversion of estrone and estra-
diol [32]. In addition to potential local effects of these enzymes
on breast tissue, ESR-estrogen interactions stimulate breast
epithelial cell growth [33]. Single-nucleotide polymorphisms
(SNPs) in genes encoding sex steroid-metabolizing enzymes
or receptors have effects on the hormonal milieu of the breast
and on levels of potential mammary carcinogens [6].
A few studies have explored associations between mammo-
graphic density and SNPs in genes encoding CYP1A1,
CYP1B1, aromatase, 17β-HSD, ESR1, and ESR2 [34-39].
However, most studies were focused on postmenopausal
women [36,37]. Premenopausal breast density may be more
highly heritable than is postmenopausal density [40], and
some genes may be associated with premenopausal but not
with postmenopausal density [4]. The goal of this study was to
examine the association between mammographic density and
SNPs in genes encoding CYP1A1, CYP1B1, aromatase, type
I 17β-HSD, ESR1, and ESR2 in a group of pre- and early per-
imenopausal white, African-American, Chinese, and Japanese
women.
Materials and methods
To determine the association between SNPs in genes encod-
ing sex steroid-metabolizing enzymes and ESRs and mammo-
graphic density, we used data from women who participated
in the SWAN ancillary Mammographic Density Study and the
SWAN Genetics Study, which are described later. All proto-
cols were IRB approved at participating sites, and all partici-
pating women provided signed, written informed consent.
The Study of Women's Health Across the Nation (SWAN)
SWAN is a multisite longitudinal community-based cohort
study of 3,302 midlife women, serving as the parent study for
the Mammographic Density ancillary study. In brief, at base-
line, women were aged 42 to 52 years and premenopausal
(reporting no change in usual menstrual pattern) or early peri-
menopausal (reporting change in menstrual pattern but occur-
rence of menstruation in the past 3 months), had an intact
uterus and one or more ovaries, were not pregnant or lactating,
and were not using exogenous reproductive hormones [41].
Initiation of exogenous hormones after the baseline visit did
not preclude inclusion in the longitudinal cohort study. Each of
the seven study sites enrolled white women in addition to
women of one other self-identified racial/ethnic group: African-
American women (Boston, Detroit area, Chicago, and Pitts-
burgh), Japanese women (Los Angeles), Hispanic women
(New Jersey), and Chinese women (Oakland, California).
SWAN participants completed questionnaires and underwent
fasting blood sampling annually.
The SWAN Mammographic Density Study
Three SWAN clinical sites (Los Angeles, Oakland, Pittsburgh)
participated in the SWAN Mammographic Density ancillary
study, which retrieved and analyzed existing participants'
mammograms that had been performed by accredited mam-
mography facilities as a part of routine medical care.
At the time of enrollment into the ancillary study, 1,248 partic-
ipants were active at the three sites. Of these, 22 (2%) women
were ineligible because of bilateral breast surgery, 82 (7%)
were not recruited because of having an abbreviated follow-
up, and 89 (7%) refused to participate. Thus, 1,055 (85%)
women were eligible and agreed to participate in the mammo-
graphic density study; of these, 1,005 women had at least one
mammographic density assessment.
By using previously published methods, a single expert
reviewer quantified mammographic density (that is, the per-
centage of the breast composed of dense tissue) [42]. The
reader assessed mammographic density by using the cranio-
caudal view of the mammogram of the right breast [43]. If a
participant reported prior breast surgery involving the right
breast, mammograms of the left breast were used for density
assessments. A compensating polar planimeter was used to
measure the total breast area (in square centimeters) and the
area of dense breast tissue (in square centimeters). Percent-
age density was calculated as the area of dense breast tissue
divided by the area of the breast. A repeated review of a 10%
random subset of mammograms for intrarater reliability yielded
an intraclass correlation coefficient for percentage mammo-
graphic density of 0.96 [43].Page 2 of 15
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graphic density among pre- and early perimenopausal partici-
pants. Of the 1,005 participants with at least one assessment
of mammographic density, we chose one mammogram for
each of the 643 pre- or early perimenopausal SWAN Mammo-
graphic Density study participants. If more than one mammo-
gram was available for given participant, we selected the
mammogram temporally closest to the preceding annual fol-
low-up visit that was flanked by pre- or early perimenopausal
status on the visits before and after the mammogram. For
example, if a participant had mammographic density assess-
ments from two mammograms during her premenopausal
stage and one mammogram during her early perimenopausal
stage, we chose a single mammogram for the participant by
picking the mammogram that was temporally closest to its pre-
ceding annual follow-up visit. Mammograms that occurred
more than 3 months before baseline and mammograms
obtained during the use of current exogenous reproductive
hormones were excluded.
The SWAN Genetics Study
The SWAN Genetics Study genotyped 25 SNPs relating to
sex-steroid metabolism and estrogen receptors (Figure 1,
Table 1). Of the 1,988 women who were eligible (that is, still
participating and providing blood for the SWAN parent study
at the follow-up year 5 visit), 88% agreed to participate in the
genetics study. Details regarding specimen collection, speci-
men processing, and genotyping were previously reported
[44]. Genotyping was performed by using TaqMan (Roche
Molecular Systems, Inc., Pleasanton, CA) and an ABI 7900 HT
sequence detection system (Applied Biosystems Inc., Foster
City, CA, USA).
Between three and eight SNPs per gene were selected based
on use in previous genetics studies, a review of the literature,
and information from gene databases (National Center for Bio-
technology SNP database [45] and Celera [46]). The original
SNP selection process is discussed in the first SWAN Genet-
ics Study manuscript [44]. The SWAN Genetics Study
searched for published literature supporting the biologic sig-
nificance of SNPs chosen. SNPs were chosen if they were
thought potentially to influence circulating sex hormone levels
[47,48] or disease patterns: breast cancer [49-51], ovarian
cancer [52], and bone mineral density [53,54].
Of the 643 premenopausal or early perimenopausal SWAN
participants with available mammographic density information,
at least partial genotyping data were available for 463 (72%)
women. For this analysis, we excluded one participant lacking
genotyping data for 24 of the 25 SNPs and an additional 11
participants who were missing information for one or more
covariates. Thus, the analytic sample for this study comprised
the 451 pre- and early perimenopausal women for whom com-
plete information was available regarding mammographic den-
sity, genotypes, and covariates.
Questionnaire-based and anthropometric measures
At baseline and at each annual follow-up visit, SWAN partici-
pants were asked to complete standardized questionnaires
and underwent measurement of height and weight for calcula-
tion of body mass index (BMI, weight in kilograms divided by
the square of the height in meters). We took information
regarding age, race/ethnicity, reproductive history, medication
use, smoking, and alcohol intake from annual questionnaires.
Statistical analysis
Allele frequencies in the SWAN Genetics Study were esti-
mated by race/ethnicity (Mendel Version 8.0 [55]). Hardy-
Weinberg equilibrium (HWE) was assessed by using Fisher's
Exact tests [55]. Because of the multiple statistical tests per-
formed, we considered a P value of < 0.01 as the criterion to
reject the null hypothesis of HWE.
Creating a separate model for each of the 25 SNPs, we used
multivariate linear regression to examine the relation between
percentage mammographic breast density (outcome) and
SNP (primary predictor). Based on previously published stud-
ies, we considered the following candidate covariates: age,
race/ethnicity, number of live births, BMI, oral contraceptive
use, menopausal hormone use, cigarette smoking, and alcohol
intake) [3,43,56-68]. Of these candidate covariates, age,
number of live births, and BMI were included in all models,
based on previously well-established associations with mam-
mographic density. The remaining candidate covariates (ciga-
rette smoking, alcohol intake, oral contraceptive use, and
menopausal hormone use) were evaluated for model inclusion
by using backwards regression performed on data from the
643 pre- and early perimenopausal participants of the SWAN
Mammographic Density study. We used a P value of 0.10 as
the cutoff for covariate inclusion. In addition, because each
site recruited a specific racial/ethnic group in addition to non-
Figure 1
Functions of SWAN genetics sex steroid metabolism enzymes and recept r
receptors. Used with permission of Sowers and colleagues [93].Page 3 of 15
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Table 1
SNPs examined in the SWAN Genetics Study
rs Number Other common designation of SNP Affected allelesa Region of affected DNA sequence Change in amino acid
17-β HSD chromosome 17q11-q21
rs615942 HSD615942b G/T Missense, amino acid position 55, codon 
position 2, C → A exon 2 Ser → Tyr
rs592389 HSD592389 G/T 3' Near gene N/A
rs2830 HSD17B2830 A/G 5' Untranslated region exon 1 N/A
ESR1 chromosome 6q25.1
rs9340799 ESRA464, XbaI RFLP A/G Intron 1 N/A
rs2234693 ESRA418, PvuII RFLP T/C Intron 1 N/A
rs728524 ESR728524 A/G Intron 4 N/A
rs3798577 ESR3798577 T/C 3' Untranslated region exon 8 N/A
ESR2 chromosome 14q23.2
rs1256030 ESR1256030 C/T Intron 2 N/A
rs1255998 ESR1255998 C/G 3' Untranslated region exon 9 N/A
rs1256049 ESR1256049, V328V, RsaI G/A Synonymous, amino acid position 328 
(valine), codon position 3 exon 6
N/A
CYP1A1 chromosome 15q22-q24
rs2606345 CYP2606345, -1806 C/A Intron 1 N/A
rs4646903 CYP1A1250, MspI, m1, T6235C T/C 3' Near gene N/A
rs1531163 CYP1531163, -11781 promoterc A/G Synonymous, amino acid position 294 
(lysine), codon position 3 exon 8
N/A
rs1048943 CYP1048943, CYP1A1*2C, A2455G, 
m2, 6750 A>G
A/G Missense, amino acid position 462, codon 
position 1 A → G exon 7 Ile → Val
CYP1B1 chromosome 2p21
rs1800440 CYP1800440, N453S, A4390G, 
CYP1B1*4
A/G Missense, amino acid position 453, codon 
position 2 A → G exon 3 Asn → Ser
rs162555 CYP162555 d T/C Intron 2 N/A
rs1056836 CYP1056836, CYP1B1*3, Leu432Val, 
4326C>G, C1294G, m1
C/G Missense, amino acid position 432, codon 
position 1 G → C exon 3 Val → Leu
CYP19A1 chromosome 15q21.1
rs700519 CYP19R264 C/T Missense, amino acid position 264, codon 
position 1 C → T exon 7 Arg → Cys
rs2414096 CYP194096 G/A Intron 2 N/A
N/A CYP194947, hCV8234946 A/G Intron 1 N/A
rs1008805 CYP198805 T/C Intron 1 N/A
rs2446405 CYP196405a T/A Intron 1 N/A
rs2445759 CYP195759 G/T Intron 1 N/A
rs936306 CYP196306 C/T Intron 1 N/A
rs749292 CYP199292 G/A Intron 1 N/A
aReference (higher frequency) allele is listed first. bEncodes Coenzyme A synthase. cEncodes lectin, mannose-binding, 1-like. dEncodes LOC732 
hypothetical protein. eEncodes gliomedine.
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ethnicity and study site; this variable was included in all mod-
els. Categories for this variable were whites in Oakland, Chi-
nese in Oakland, whites in Los Angeles, Japanese in Los
Angeles, white in Pittsburgh, or African American in Pitts-
burgh. Age at mammogram (continuous), race/ethnicity-study
site, number of live births (continuous), current cigarette smok-
ing (yes/no), and BMI (continuous) were the covariates
retained in the final models. We modeled the alleles as acting
in either an additive (aa versus Aa and AA, where the effect of
the Aa genotype is half the effect of the AA genotype) or
recessive (aa/Aa versus AA) manner, in which A is the minor
allele.
Because of prior studies showing that associations of sex ster-
oid-related SNPs may be more evident among women with
BMI greater than 25 [69], we conducted secondary analyses
wherein we added an SNP*BMI interaction term to the multi-
variable linear regression models. Because we suspected that
the sample size of certain racial/ethnic subgroups may have
been too small to allow detection of SNP*race/ethnicity inter-
actions, and because the allele frequencies for 13 of the 25
SNPs differed by more than 0.20 between the ethnic groups,
we repeated all of our analyses in the subsample of white par-
ticipants, the largest racial/ethnic subgroup. All regression
analyses were performed with the software program R [70].
Results
Baseline characteristics of the participants
Baseline characteristics of the analytic sample (N = 451 with
mammographic density, genotyping, and covariate data) are
displayed in Table 2. No notable differences in characteristics
were found between the overall mammographic density sam-
ple (N = 643) and the analytic sample. The median age of the
participants in the analytic sample was 48.7 years (Table 2).
Median BMI was 24.4 kg/m2. Mean percentage mammo-
graphic density was 43.6%. Forty-nine percent of the partici-
pants in the analytic sample were white, 24% were Chinese,
22% were Japanese, and 6% were African American. Twenty-
six percent were premenopausal, and 74% were early peri-
menopausal at the visit immediately preceding mammography
(Table 2).
Hardy-Weinberg Equilibrium assessment
We examined allele frequencies by ethnicity (Table 3) and
assessed HWE (see Table 4). Within racial/ethnic subgroups,
only CYP194947 showed significant deviation from HWE.
Because this SNP was also the SNP with the highest fre-
quency (8%) of missing genotypes, methodologic considera-
tions related to genotyping of this SNP may have contributed
to deviation from HWE.
Associations between SNPs and percentage 
mammographic density
We examined the association between percentage mammo-
graphic breast density and each of the SNPs in models
adjusted for age, race/ethnicity-study site, parity, smoking, and
BMI (Tables 5 and 6).
In the fully adjusted recessive models (adjusted for age, race/
ethnicity-study site, parity, smoking, and BMI), the CYP1B1
rs162555 CC genotype was associated with 9.4% higher
percentage mammographic density than the TC/TT genotype
(P = 0.04). The CYP19A1 rs936306 TT genotype was asso-
ciated with 6.2% lower percentage mammographic density
than TC/CC genotype (P = 0.03) (Table 5). In contrast to anal-
yses restricted to white participants, ESR1 rs2234693 was
not significantly associated with mammographic density in
either recessive or additive models that included the entire
analytic sample (Tables 5 and 6).
Interaction by BMI
In additive models, CYP1A1 rs2606345 was significantly
associated with BMI (1.1 kg/m2 higher for each A allele; P =
0.03) and CYP19A1 rs2414096 (1.1 kg/m2 lower for each A
allele; P = 0.01; data not shown). Similarly, in recessive mod-
els restricted to white participants, the CYP194947 GG gen-
otype was associated with a 2.1 kg/m2 lower BMI compared
with the GA/AA genotype (P = 0.05), and the CYP19A1
rs749292 AA genotype was associated with a 2.3 kg/m2
lower BMI than the GA/GG genotype (P = 0.05; data not
shown).
To determine whether associations between SNPs and mam-
mographic density varied according to BMI, we added
BMI*SNP interaction terms to multiple linear regression mod-
els that included age, race/ethnicity-study site, smoking, par-
ity, and BMI as covariates and percentage mammographic
density as the outcome (data not shown). In additive models,
the CYP1A1 rs2606345-mammographic density association
was significantly different (stronger) among participants with
BMIs greater than 30 kg/m2 compared with participants with
BMIs less than 25 kg/m2 (Pinteraction = 0.05). Specifically,
among participants with BMIs less than 25 kg/m2, percentage
mammographic density was 0.57% higher for each CYP1A1
rs2606345 C allele; in contrast, among participants with BMIs
greater than 30 kg/m2, percentage mammographic density
was 6.1% higher for each additional C allele. The associations
of SNPs with mammographic density did not significantly differ
by BMI category for CYP19A1 rs2414096, CYP19A1
rs749292, or CYP194947. However, we may not have had
adequate statistical power to detect an SNP*BMI interaction
when BMI was categorized into tertiles.
Analyses restricted to white participants
In analyses restricted to whites (n = 219), we detected two
associations that were similar to those seen in the overall ana-Page 5 of 15
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models, CYP19A1 rs2414096 in additive models). In white
participants, the ESR1 rs2234693 CC genotype was associ-
ated with a 7.0% higher percentage mammographic density
than the CT/TT genotype (P = 0.01; Table 5); this finding was
also apparent in additive models (P = 0.01; Table 6). The
association between ESR1 rs2234693 and mammographic
density varied by ethnicity; the association was stronger
among whites than among Japanese (interaction P value,
0.09) or Chinese (interaction P value, 0.03) participants.
Discussion
In pre- and early perimenopausal women, SNPs involving
CYP1B1 (rs162555 CC genotype), CYP19A1 (rs936306
TT/CC genotype), and ESR1 (rs2234693 CC genotype)
were each significantly positively associated with mammo-
graphic density. Associations between several SNPs
(CYP1A1 rs2606345, CYP194947, CYP19A1 rs749292,
CYP19A1 rs2414096) and mammographic density were
attenuated after adjustment for BMI. Percentage mammo-
graphic density varied at least 3% per allele for the statistically
significant associations. These differences in mammographic
density according to genotype are of a clinically relevant mag-
Table 2
Characteristics of the study participants: analytic sample of the current study (N = 451)
Mean SD Median Number %
Age at mammogram, years 48.6 2.6 48.7
BMI, kg/m2 25.9 5.9 24.4
<25 251 56
25–30 111 25
>30 89 20
Percentage mammographic density 43.6 19.5 44.7
Age at first full-term birth 28.1 5.5 28.0
Ethnicity
African American 26 6
White 219 49
Chinese 109 24
Japanese 97 22
Study site
Oakland 184 41
Los Angeles 169 37
Pittsburgh 98 22
Smoking currently 31 7
Menopausal status at time of mammogram
Early perimenopausal 332 74
Premenopausal 118 26
Parity
0 77 17
1 76 17
2 196 43
3 76 17
4 19 4
≥ 5 7 2
Baseline menopause stage information was missing for one participant whose baseline mammogram was chosen; the participant was early 
perimenopausal at the subsequent (first annual) visit.Page 6 of 15
(page number not for citation purposes)
Available online http://breast-cancer-research.com/content/11/4/R51
Table 3
Allele frequencies of SWAN Genetics Study participants by race/ethnicity
Estimated frequencies
Locus Allele All African White Chinese Japanese
17β-HSD
rs615942 G 0.52 0.64 0.47 0.55 0.56
T 0.48 0.36 0.53 0.45 0.44
rs592389 A 0.50 0.41 0.475 0.56 0.56
C 0.50 0.59 0.53 0.44 0.44
rs2830 A 0.50 0.59 0.53 0.44 0.44
G 0.50 0.41 0.47 0.56 0.56
ESR1
rs9340799 A 0.72 0.73 0.65 0.77 0.82
G 0.28 0.27 0.35 0.23 0.18
rs2234693 C 0.46 0.46 0.46 0.41 0.48
T 0.54 0.54 0.54 0.59 0.52
rs728524 A 0.89 0.76 0.98 0.81 0.81
G 0.11 0.24 0.02 0.19 0.188
rs3798577 C 0.46 0.41 0.48 0.45 0.45
T 0.54 0.59 0.52 0.55 0.55
ESR2
rs1256030 C 0.61 0.75 0.57 0.70 0.58
T 0.39 0.25 0.43 0.30 0.42
rs1255998 C 0.68 0.50 0.89 0.37 0.54
G 0.32 0.50 0.11 0.63 0.46
rs1256049 A 0.18 0.11 0.02 0.45 0.30
G 0.82 0.89 0.98 0.55 0.70
CYP1A1
rs2606345 A 0.37 0.18 0.66 0.06 0.05
C 0.63 0.82 0.34 0.94 0.95
rs4646903 A 0.75 0.71 0.89 0.54 0.61
G 0.25 0.29 0.11 0.46 0.39
rs1531163 A 0.88 0.66 0.95 0.84 0.80
G 0.12 0.34 0.05 0.16 0.20
rs1048943 A 0.88 0.98 0.96 0.75 0.76
G 0.12 0.02 0.04 0.25 0.24
CYP1B1
rs1800440 A 0.89 0.90 0.80 1.00 1.00
G 0.11 0.10 0.20 0.004 0.006
rs162555 C 0.12 0.16 0.19 0.04 0.01
T 0.88 0.84 0.81 0.96 0.99
rs1056836 C 0.69 0.33 0.59 0.88 0.86
G 0.31 0.67 0.41 0.12 0.14Page 7 of 15
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sity is associated with a 2% higher relative risk of breast
cancer [2]. Several SNP-mammographic density associations
varied significantly by ethnicity.
Several of our findings are novel. As far as we know, other pub-
lications have not reported information regarding associations
between mammographic density and the following SNPs:
17β-HSD rs615942, 17β-HSD rs592389, 17β-HSD rs2830,
ESR1 rs728524, ESR1 rs3798577, ESR2 rs1256030,
ESR2 rs1255998, ESR2 rs1256049, CYP1B1 rs162555,
CYP1B1 rs1800440, CYP19A1 rs700519, CYP19A1
rs2446405, CYP19A1 rs2445759, CYP19A1 rs1008805,
CYP19A1 rs936306, CYP19A1 rs2414096, CYP19A1
rs749292, CYP194947, CYP1A1 rs1531163, or CYP1A1
rs2606345.
Our finding of an association between ESR1 rs2234693 and
mammographic density among white women conflicts with
some prior studies. The association between ESR1
rs2234693 and mammographic density was described in
three reports from the EPIC study. In the first EPIC report, the
T allele was associated with higher mammographic density
[39], whereas in this study, the CC genotype is associated
with higher mammographic density.
The second EPIC analysis found a statistically significant dif-
ference in mammographic density between hormone therapy
users and never-users of hormone therapy among women the
CT or TT genotype, but not among those with the CC geno-
type [71].
The third EPIC analysis reported no association between
ESR1 rs2234693 and mammographic density [36]; the dis-
crepancy among studies may be because the previous study
used a different mammographic density measurement tech-
nique, had a less heterogenous study population, and focused
on postmenopausal women.
We found an association between CYP1B1 rs1056836 and
mammographic density that neared statistical significance
only before adjustment, but not after adjustment, for BMI.
These results may be consistent with three previously pub-
lished studies [35,36,38].
A cross-sectional observational European study of white
women found statistically significantly higher mammographic
density in carriers of at least one ESR1 rs9340799 A allele
[39]. Although we had similar results, our findings were not
statistically significant, possibly because of the smaller
number of participants in our study or the younger age of our
participants.
CYP19
rs700519 A 0.12 0.13 0.04 0.14 0.29
G 0.88 0.88 0.96 0.86 0.71
rs2414096 A 0.43 0.25 0.50 0.46 0.32
G 0.57 0.75 0.50 0.54 0.68
4947a A 0.52 0.71 0.55 0.39 0.49
G 0.48 0.29 0.45 0.61 0.51
rs1008805 C 0.36 0.16 0.42 0.28 0.37
T 0.64 0.84 0.58 0.72 0.63
rs2446405 A 0.32 0.52 0.18 0.47 0.45
T 0.68 0.48 0.82 0.53 0.55
rs936306 C 0.73 0.40 0.85 0.70 0.60
T 0.27 0.60 0.15 0.30 0.40
rs2445759 G 0.96 0.92 0.93 1.00 1.00
T 0.04 0.08 0.07 0.004 0.003
rs749292 A 0.44 0.51 0.44 0.50 0.36
G 0.56 0.49 0.56 0.50 0.64
aNo corresponding dbsnp rs number; commonly referred to as CYP194947.
Table 3 (Continued)
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Table 4
Hardy-Weinberg equilibrium evaluation by race/ethnicity
All African White Chinese Japanese
Locus P value Number P value Number P value Number P value Number P value Number
HSD
rs615942 0.0741 716 1 56 0.0691 364 0.2962 139 0.632 157
rs592389 0.0462 714 0.4159 56 0.075 361 0.3061 138 0.7462 156
rs2830 0.0356 715 0.4074 56 0.1147 362 0.1189 139 0.7504 156
ESR1
rs9340799 0.5221 720 0.1818 56 0.1726 365 0.6308 140 0.5958 157
rs2234693 0.8786 718 0.5964 56 0.5327 364 1 139 0.4255 157
rs728524 0.0724 719 0.4825 56 1 364 1 140 0.7874 157
rs3798577 0.9362 715 0.7783 55 0.8299 363 1 139 1 156
ESR2
rs1256030 0.6411 715 0.0811 56 1 363 0.1591 140 0.7379 154
rs1255998 <0.00005 712 0.2985 56 0.41 361 0.199 138 1 155
rs1256049 <0.00005 679 1 46 0.1804 344 0.3854 132 0.5638 155
CYP1A1
rs2606345 <0.00005 715 0.6693 55 0.9088 360 1 141 1 157
rs4646903 <0.00005 706 0.7502 55 0.4137 356 1 138 0.1252 155
rs1531163 0.0092 712 0.5642 56 0.5508 359 0.3384 139 0.3173 156
rs1048943 0.0001 714 1 56 1 362 0.6582 138 0.0452 156
CYP1B1
rs1800440 <0.00005 685 0.347 47 0.0629 345 1 135 1 156
rs162555 0.0033 716 1 56 0.2346 364 0.1518 138 1 156
rs1056836 <0.00005 704 0.0591 53 0.2778 355 1 139 0.3159 155
CYP19
rs700519 0.0756 712 0.1854 56 1 360 0.0694 138 0.7032 156
rs2414096 0.9384 719 0.7184 56 0.1193 365 0.2394 141 0.3603 155
4947a¶ <0.00005 654 0.0195 41 0.5857 344 <0.00005 129 <0.00005 138
rs1008805 0.7465 717 0.6143 56 0.2444 364 0.2942 140 0.7366 155
rs2446405 0.0376 716 0.7845 55 0.7187 364 0.6048 139 0.7456 156
rs936306 0.0031 717 1 56 0.3074 364 0.552 140 0.7366 155
rs2445759 1 682 1 45 1 344 1 135 1 156
rs749292 0.6463 715 0.4183 55 0.2371 361 0.6075 141 1 156
aNo corresponding dbsnp rs number; commonly referred to as CYP194947.
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Table 5
Percentage mammographic density as a function of single-nucleotide polymorphism: recessive modelsa
Entire analytic sample (N = 451) Whites only (N = 219)
Age, race/ethnicity-study site,b parity, smoking, body mass index Age, study site, parity, smoking, body mass index
Locus β SD P value β SD P value
17-β HSD
rs615942 G -0.18 1.73 0.92 0.78 2.55 0.76
rs592389 A -0.81 1.71 0.64 0.97 2.55 0.70
rs2830 A 1.75 1.65 0.29 2.69 2.59 0.30
ESR1
rs9340799 A 4.40 2.79 0.12 6.67 3.50 0.06
rs2234693 T 3.37 1.81 0.06 7.04 2.67 0.01
rs728524 A 1.43 5.33 0.79 N/A N/A N/A
rs3798577 T 3.04 1.79 0.09 1.14 2.75 0.68
ESR2
rs1256030 C 0.72 2.10 0.73 0.80 2.94 0.79
rs1255998 C -0.14 2.25 0.95 -11.59 11.92 0.33
rs1256049 G -5.58 3.21 0.08 -6.98 16.85 0.68
CYP1A1
rs2606345 C -0.21 2.15 0.92 -0.09 2.32 0.97
rs4646903 A 0.83 2.45 0.73 -1.11 6.45 0.99
rs1531163 A 0.09 4.47 0.98 -5.50 16.87 0.74
rs1048943 A 1.14 3.99 0.77 N/A N/A N/A
CYP1B1
rs1800440 A -2.29 3.92 0.56 -1.35 4.50 0.76
rs162555 T 9.36 4.62 0.04 8.23 5.45 0.13
rs1056836 C 2.48 2.51 0.33 1.37 3.07 0.66
CYP19A1
rs700519 G -4.59 6.12 0.45 N/A N/A N/A
rs2414096 G -0.83 1.94 0.67 1.33 2.81 0.64
CYP194947¶ A 1.30 1.68 0.44 3.93 2.83 0.17
rs1008805 T -3.56 2.24 0.11 -2.36 3.07 0.44
rs2446405 T 1.99 2.31 0.39 -4.96 5.78 0.39
rs936306 C -6.17 2.82 0.03 -16.36 5.96 0.01
rs2445759 G -7.30 9.18 0.43 -10.36 11.98 0.39
rs749292 G 0.40 1.93 0.84 3.53 2.98 0.24
aReference allele was the allele with the higher frequency in the overall analytic sample and is indicated in the first column for each SNP.
bBecause each site recruited a specific racial/ethnic group in addition to non-Hispanic whites, a combined variable was created for race/ethnicity 
and study site.
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Table 6
Percentage mammographic density as a function of single-nucleotide polymorphism: additive modelsa
Entire analytic sample (N = 451) Whites only (N = 219)
Age, race/ethnicity-study siteb, parity, smoking, body mass index Age, study site, parity, smoking, body mass index
LOCUS β SD P value β SD P value
17-β HSD
rs615942 G -0.68 1.02 0.50 -0.68 1.55 0.66
rs592389 G -1.01 1.02 0.32 -0.59 1.56 0.71
rs2830 A 1.05 1.01 0.30 0.63 1.56 0.69
ESR1
rs9340799 A 1.58 1.22 0.20 3.11 1.77 0.08
rs2234693 T 1.44 1.06 0.18 4.08 1.61 0.01
rs728524 A 3.35 1.77 0.06 -9.14 6.50 0.16
rs3798577 T 1.01 1.05 0.34 -0.36 1.65 0.83
ESR2
rs1256030 C 0.79 1.10 0.47 0.76 1.64 0.64
rs1255998 C -0.42 1.30 0.75 -2.38 2.61 0.36
rs1256049 G -1.02 1.53 0.51 -2.28 4.34 0.60
CYP1A1
rs2606345 C -1.32 1.40 0.34 -1.00 1.69 0.56
rs4646903 T 1.49 1.19 0.21 1.34 2.25 0.55
rs1531163 A -0.33 1.60 0.84 -4.51 3.70 0.23
rs1048943 A 0.20 1.55 0.90 1.19 4.05 0.77
CYP1B1
rs1800440 A 0.72 1.58 0.65 1.73 1.84 0.35
rs162555 T 0.52 1.64 0.75 0.45 2.01 0.82
rs1056836 C -0.37 1.22 0.78 -1.39 1.62 0.39
CYP19A1
rs700519 C 1.59 1.72 0.36 -3.46 4.00 0.39
rs2414096 G 0.77 1.11 0.49 2.75 1.74 0.12
CYP194947c A 0.99 0.96 0.30 2.67 1.62 0.10
rs1008805 T -0.02 1.12 0.99 -0.65 1.66 0.70
rs2446405 T 0.81 1.20 0.50 -3.02 2.05 0.14
rs936306 C -0.92 1.25 0.46 -3.67 2.12 0.09
rs2445759 G -3.47 2.36 0.14 -5.19 2.86 0.07
rs749292 G 0.67 1.08 0.53 2.83 1.67 0.09
aReference allele was the allele with the higher frequency in the overall analytic sample and is indicated in the first column for each SNP. bBecause 
each site recruited a specific racial/ethnic group in addition to non-Hispanic whites, a combined variable was created for race/ethnicity and study 
site. cNo corresponding dbsnp rs number; commonly referred to as CYP194947.
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gen receptors were not significantly associated with mammo-
graphic density in the present study. As with our study, past
studies reported absence of an association between mammo-
graphic density and CYP1A1 rs1048943 and CYP1A1
rs4646903 [35,38].
Although previously published studies have not included a
systematic examination of sex steroid metabolism SNPs and
mammographic density, some previously studied SNPs may
be linked with the SNPs that we examined. We searched Hap-
loview version 4.1 (Daly Lab, Cambridge, MA) with Hapmap
genotype data to search for information regarding linkage dis-
equilibrium for each of the three SNPs that we found to be
associated with mammographic density and other SNPs pre-
viously studied in relation to mammographic density. Linkage
diseqilibrium R2 values for ESR1A1 rs2234693 (which we
found to be associated with mammographic density) and
rs9340799 (which prior studies found to be associated with
mammographic density) range from 0.234 to 0.55, depending
on the ethnic group. For CYP19A1 rs936306 (which we
found to be associated with mammographic density) and
rs10046 (which prior studies found not to be associated with
mammographic density), R2 values range from 0.017 to 0.193.
Linkage-disequilibrium information is not currently available for
CYP1B1 rs162555 on Hapmap. Although LD information was
not available for rs162555, we note that its chromosomal loca-
tion is not close to the other two previously studied CYP1B1
SNPs.
Our findings have a biologic rationale. A local influence of sex
steroid metabolism SNPs on breast tissue is suggested by
prior breast cancer studies. For example, ESR1 rs2234693
has been associated with duration of breast cancer survival
[72], degree of breast cancer differentiation [73], age at
breast cancer diagnosis [74], and receptor status of breast
cancer tumors [75,76]. Likewise, CYP19A1 rs936306 may
be associated with breast cancer disease-free survival [77].
Case-control studies of breast cancer risk related to ESR1
rs2234693 [73,76,78-87] and in relation to CYP19A1
rs936306 [77,88] are conflicting. Inconsistent results of
breast cancer case-control studies are likely due to differ-
ences in ethnicity and menopausal status of participants
across studies. Reasons exist to suspect that associations of
SNPs with mammographic density may vary by BMI, as we
found for CYP1A1 rs2606345. Sex steroid metabolism (for
example, peripheral aromatization of androstenedione) varies
by BMI, so that effects of sex steroid SNPs on breast tissue
may be more pronounced among obese women. Although
prior studies have not examined whether associations of
CYP1A1 rs2606345 with mammographic density vary by
BMI, a prior study reported that the association of an ESR1
SNP with increased breast cancer risk was apparent only
among women with BMI greater than 25 kg/m2 [69].
Strengths of our study included its multiethnic study popula-
tion, use of validated and reproducible mammographic den-
sity-assessment techniques, rigorous attention to genotyping
methods, and collection of detailed information regarding key
covariates related to mammographic density. However, this
study did not directly assess sex steroid activity in breast tis-
sue samples. Furthermore, although our sample size was rela-
tively large, its heterogeneity may have precluded detection of
statistically significant race-specific associations or interac-
tions of SNPs with mammographic density. Finally, the obser-
vational study design precluded coordination of
mammographic density with menstrual-cycle phase. Relations
between SNPs and mammographic density may have been
diluted because we analyzed mammograms taken during var-
ying menstrual phases. Breasts are more radiographically
dense during the luteal phase [89-91], although a recent study
found that variation in mammographic density over the men-
strual cycle may be subtle (that is, may not be statistically sig-
nificant) [92].
Conclusions
In conclusion, SNPs involving sex steroid metabolism enzymes
and ESR1 may be associated with mammographic density in
pre- and early perimenopausal women. Future studies relating
these SNPs to mammographic density not only should adjust
for BMI but also should consider interactions by BMI. The
mechanisms underlying the association (for example,
increased proliferation of epithelial and stromal cells) require
elucidation. Because these enzymes and ESR1 are expressed
in target tissues, these SNPs (or genetic factors with which
they are in linkage disequilibrium) may alter breast cancer risk
by altering mammographic density. These findings inform the
understanding of biologic influences on mammographic den-
sity, a strong risk factor for breast cancer.
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